Practical Guidelines for Assessing the Clinical Significance of Health-Related Quality of Life Changes within Clinical Trials

Jeff A Sloan, Tara Symonds, Delfino Vargas-Chanes, Brooke Fridley

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Health-related quality of life (HRQOL) assessment is becoming common practice in many clinical trials. There is much debate over how to determine the clinical significance of changes in HRQOL scores. A number of techniques have been used to address this issue. This paper reviews the most popular of these approaches for use in a clinical trial setting. More specifically, the anchor-based “minimal clinically important difference” technique is described and critiqued, as is the more traditional distribution-based effect size technique. A novel application of effect size, which applies a common statistical premise known as the empirical rule, is also presented. The review of these techniques indicates that there is no single, optimal solution to determining clinical significance of changes in HRQOL scores. However, it is encouraging to note that they ail suggest a similar criterion of a half-standard deviation for whether or not a change in HRQOL score is clinically significant. Recommendations are given for reporting the clinical significance of HRQOL assessments in clinical trials.

Original languageEnglish (US)
Pages (from-to)23-31
Number of pages9
JournalTherapeutic Innovation and Regulatory Science
Volume37
Issue number1
DOIs
StatePublished - 2003

Fingerprint

Quality of Life
Clinical Trials
Guidelines

Keywords

  • Clinical significance
  • Effect size
  • HRQOL
  • Minimal clinically important difference
  • Psychometrics

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Cite this

Practical Guidelines for Assessing the Clinical Significance of Health-Related Quality of Life Changes within Clinical Trials. / Sloan, Jeff A; Symonds, Tara; Vargas-Chanes, Delfino; Fridley, Brooke.

In: Therapeutic Innovation and Regulatory Science, Vol. 37, No. 1, 2003, p. 23-31.

Research output: Contribution to journalArticle

@article{5f641290fe3147c68664b08ef24629c5,
title = "Practical Guidelines for Assessing the Clinical Significance of Health-Related Quality of Life Changes within Clinical Trials",
abstract = "Health-related quality of life (HRQOL) assessment is becoming common practice in many clinical trials. There is much debate over how to determine the clinical significance of changes in HRQOL scores. A number of techniques have been used to address this issue. This paper reviews the most popular of these approaches for use in a clinical trial setting. More specifically, the anchor-based “minimal clinically important difference” technique is described and critiqued, as is the more traditional distribution-based effect size technique. A novel application of effect size, which applies a common statistical premise known as the empirical rule, is also presented. The review of these techniques indicates that there is no single, optimal solution to determining clinical significance of changes in HRQOL scores. However, it is encouraging to note that they ail suggest a similar criterion of a half-standard deviation for whether or not a change in HRQOL score is clinically significant. Recommendations are given for reporting the clinical significance of HRQOL assessments in clinical trials.",
keywords = "Clinical significance, Effect size, HRQOL, Minimal clinically important difference, Psychometrics",
author = "Sloan, {Jeff A} and Tara Symonds and Delfino Vargas-Chanes and Brooke Fridley",
year = "2003",
doi = "10.1177/009286150303700105",
language = "English (US)",
volume = "37",
pages = "23--31",
journal = "Therapeutic Innovation and Regulatory Science",
issn = "2168-4790",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Practical Guidelines for Assessing the Clinical Significance of Health-Related Quality of Life Changes within Clinical Trials

AU - Sloan, Jeff A

AU - Symonds, Tara

AU - Vargas-Chanes, Delfino

AU - Fridley, Brooke

PY - 2003

Y1 - 2003

N2 - Health-related quality of life (HRQOL) assessment is becoming common practice in many clinical trials. There is much debate over how to determine the clinical significance of changes in HRQOL scores. A number of techniques have been used to address this issue. This paper reviews the most popular of these approaches for use in a clinical trial setting. More specifically, the anchor-based “minimal clinically important difference” technique is described and critiqued, as is the more traditional distribution-based effect size technique. A novel application of effect size, which applies a common statistical premise known as the empirical rule, is also presented. The review of these techniques indicates that there is no single, optimal solution to determining clinical significance of changes in HRQOL scores. However, it is encouraging to note that they ail suggest a similar criterion of a half-standard deviation for whether or not a change in HRQOL score is clinically significant. Recommendations are given for reporting the clinical significance of HRQOL assessments in clinical trials.

AB - Health-related quality of life (HRQOL) assessment is becoming common practice in many clinical trials. There is much debate over how to determine the clinical significance of changes in HRQOL scores. A number of techniques have been used to address this issue. This paper reviews the most popular of these approaches for use in a clinical trial setting. More specifically, the anchor-based “minimal clinically important difference” technique is described and critiqued, as is the more traditional distribution-based effect size technique. A novel application of effect size, which applies a common statistical premise known as the empirical rule, is also presented. The review of these techniques indicates that there is no single, optimal solution to determining clinical significance of changes in HRQOL scores. However, it is encouraging to note that they ail suggest a similar criterion of a half-standard deviation for whether or not a change in HRQOL score is clinically significant. Recommendations are given for reporting the clinical significance of HRQOL assessments in clinical trials.

KW - Clinical significance

KW - Effect size

KW - HRQOL

KW - Minimal clinically important difference

KW - Psychometrics

UR - http://www.scopus.com/inward/record.url?scp=84996253416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996253416&partnerID=8YFLogxK

U2 - 10.1177/009286150303700105

DO - 10.1177/009286150303700105

M3 - Article

VL - 37

SP - 23

EP - 31

JO - Therapeutic Innovation and Regulatory Science

JF - Therapeutic Innovation and Regulatory Science

SN - 2168-4790

IS - 1

ER -